INFORMAZIONI SU QUESTO EPISODIO
Who are the likely beneficiaries of more nuanced diabetes treatments, and how might these agents advance diabetes care? Silvio Inzucchi, MD, and guest Joshua Neumiller, PharmD, dig deep into recent drug developments.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/963278). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022 https://diabetesjournals.org/care/article/45/Supplement_1/S125/138908/9-Pharmacologic-Approaches-to-Glycemic-Treatment
Patient Education Interventions Improve A1C Values https://pubmed.ncbi.nlm.nih.gov/35426637/
Therapeutics for Type-2 Diabetes Mellitus: A Glance at the Recent Inclusions and Novel Agents Under Development for Use in Clinical Practice https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474306/
Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes—2022 https://diabetesjournals.org/care/article/45/Supplement_1/S39/138909/3-Prevention-or-Delay-of-Type-2-Diabetes-and
